Fosanis, Berlin, GermanyA digital health company that is based in Canada that develops Mika, a prescription DTx for all oncological indications, closed a series A funding round of more than €10m.
Theround was led Debiopharm Innovation FundParticipation from Ananda Impact Ventures, and Ship2B Ventures Equity Pitcher.
TheCompany will no longer use funds to expand internationally.
Founded in2017 by Dr Gandolf Finke and Dr Jan Simon Raue, Fosanis has developed the AI-powered DTx Mika in collaboration with oncological research institutions cancer centres such as the UniversityThis is Leipzig Medical Center Charité Berlin. Mika is a personalised digital therapeutic (DTx) platform inOncology provides evidence-based digital interventions to support patients with cancer. inHow to cope with the challenges of the disease process and treatment. Daily check-ups – so-called ePROs = electronic patient-reported outcomes – allow continuous tracking of distress levels and symptoms, while a personalised coaching programme provides scientifically validated multi-media elements and psychooncological interventions. These include over 800 rigorously validated articles, videos and coping skills training courses – ranging from nutrition recommendations to physical exercise training and mindfulness coaching.
FosanisMore than 40 people are employed.